Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.
You may also be interested in...
Zydus Becomes A Part Of History As It Loses On US Canagliflozin Patents
ANDA sponsor Zydus Cadila has failed to convince a US district court that three patents shielding the Invokana/Invokamet brands were invalid, as it became a little part of history in one of the major trials to be held amid the coronavirus pandemic.
Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?
New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.
Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.